← Search & browse all drugs
RESPIRATORY SYSTEM › COUGH AND COLD PREPARATIONS › COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS › Other cough suppressants
pipazetate
R05DB11
Forms & Strengths
- Oral syrup 5 mg/mL
- Tablets 10 mg and 30 mg
- Oral lozenges 10 mg
Adult Dosing
- 15–30 mg orally every 4–6 h as needed (max 120 mg/24 h)
- Syrup: 5–10 mL (25–50 mg) every 4–6 h
Pediatric Dosing
- Age ≥2 yr: 5–10 mg orally every 6–8 h (max 30 mg/24 h)
- Weight‑based: 0.5–1 mg/kg per dose, not to exceed 30 mg/day
- Not recommended under 2 yr
Indications
- Symptomatic relief of dry, non‑productive cough associated with common cold, acute bronchitis or upper respiratory infections
Mechanism of Action
- Central cough‑center depression in the medulla oblongata
- Inhibition of peripheral afferent vagal cough reflex
- Mild local anesthetic effect on airway sensory endings
Contraindications
- Known hypersensitivity to pipazetate or excipients
- Severe hepatic impairment
- Acute asthmatic bronchospasm (risk of secretion thickening)
- Children <2 yr
Adverse Reactions
- Drowsiness or somnolence
- Dry mouth, taste alteration
- Nausea, vomiting, abdominal discomfort
- Constipation
- Transient dizziness or light‑headedness
- Skin rash or urticaria (rare)
- Transient elevation of hepatic enzymes
Drug Interactions
- Additive CNS depression with alcohol, sedatives, antihistamines or opioid antitussives
- Anticholinergic additive effects with other anticholinergic drugs
- Potential CYP3A4 inhibition/induction altering levels of concomitant drugs metabolized by this pathway
- Avoid concurrent MAO‑inhibitors due to possible exaggerated CNS effects
Curated Content: Needs Vetting Before Put to Clinical Use